3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Conditions
Breast Neoplasms
3
Urinary Bladder Neoplasms
1
Ureteral Neoplasms
1
Pancreatic Neoplasms
1
Pain
1
Ovarian Neoplasms
1
Osteoporosis
1
Neoplasms
1
Neoplasm, Residual
1
Myelodysplastic Syndromes
1
Lymphoma
1
Leukemia
1
Kidney Neoplasms
1
Giant Cell Tumor of Bone
1
Depression
1
Colonic Polyps
1
Carcinoma, Transitional Cell
1
Body Weight Changes
1
Arthralgia
1
Adenomatous Polyps
1
Interventions
blinatumomab
9
Cyclophosphamide
7
Rituximab
6
Lenalidomide
6
Dexamethasone
5
Azacitidine
5
venetoclax
4
fludarabine
4
Cytarabine
4
fludarabine phosphate
3
Maintenance
3
Busulfan
3
tislelizumab
2
thymoglobulin
2
pembrolizumab
2
obinutuzumab
2
daratumumab
2
Whole-Body Irradiation
2
N,N-dicyclohexyl-isoborneol-10-sulfonamide
2
Methotrexate
2
Melphalan
2
Immunotherapy
2
Imatinib Mesylate
2
Drug Therapy
2
Docetaxel
2
Decitabine
2
Clofarabine
2
Cladribine
2
Carboplatin
2
Calcium Dobesilate
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Neoplasm, Residual
×
Calcium
×
Clear all
NCT00172068
2009-12-23
MRD-1
Novartis
Phase 2
Terminated
96 enrolled